A Review of Pramlintide in the Management of Diabetes
|
|
- Dominick Melton
- 6 years ago
- Views:
Transcription
1 REVIEW A Review of in the Management of Diabetes Caroline Messer and Dina Green Department of Endocrinology, Diabetes and Bone Disease, Mount Sinai School of Medicine, New York, New York 129, U.S.A. Abstract: Tight glycemic control in type 1 and type 2 diabetes reduces the risk for microvascular complications, including retinopathy, nephropathy, and neuropathy. Yet, despite intensive insulin regimens, many insulin-dependent patients are unable to achieve euglycemic states. This review will focus on pramlintide, an equipotent amylin analog, and its role in the management of diabetes. lowers glucose through the same mechanisms as amylin: it slows gastric emptying, suppresses the postprandial rise of glucagon in patients with diabetes, and promotes satiety. Long-term clinical trials have shown that the use of pramlintide as an adjunct to insulin minimizes postprandial glucose excursions and reduces both HbA 1C and body weight when compared to placebo. Although its effects on HbA 1C are modest, pramlintide has gained popularity as a result of its relatively few contraindications, limited side effects, minimal risk for hypoglycemia, and potential for weight loss. The combination of insulin and pramlintide may provide an effective means for patients with diabetes to meet their HbA 1C goals. Keywords: diabetes, amylin, pramlintide, HbA 1C, insulin, gastric emptying, postprandial glucagon, weight, hypoglycemia Diabetes affects 23.6 million people in the United States, or 8% of the population. Diabetic retinopathy is the leading cause of new cases of blindness in adults between the ages of 2 and 74, affecting between 12, and 24, patients yearly. It is also the leading cause of renal failure in the United States. In 25, 46,739 people with diabetes began treatment for end-stage renal disease. The ADA estimates that 6% to 7% of patients with diabetes exhibit nervous system damage in the form of impaired sensation or pain in the extremities, slowed transit of food through the stomach, or carpal tunnel syndrome (ADA 28). It is well established that tight glycemic control in type 1 and type 2 diabetes reduces the risk for microvascular complications, including retinopathy, nephropathy, and neuropathy (DCCT 1993, UKPDS 1998). Furthermore, any decrease in the HbA 1C appears to confer this advantage (DCCT 1996). Despite intensive insulin use, many insulin-dependent patients are unable to achieve euglycemic states (DCCT 1993; UKPDS 1998). Deterrents to goal HbA 1C s include weight gain with insulin and difficulty controlling postprandial rises in blood glucose. 1 The weight gain caused by insulin is not only cosmetically undesirable but also increases cardiovascular risk and the incidence of metabolic syndrome. Insulin therapy alone is often unable to sufficiently mimic endogenous postprandial surges in insulin and amylin. This review will focus on pramlintide, an equipotent amylin analog, and its role in the management of type 1 and type 2 diabetes. In 25, the FDA approved its use at mealtimes for both type 1 and insulintreated type 2 diabetes. In type 1 diabetes, it is used as an adjunct treatment in patients already optimized with preprandial insulin and basal insulin but unable to achieve target glucose levels. In type 2 diabetes, it is similarly used as an adjunct treatment in patients already using preprandial and basal insulin with or without concurrent sulfonylurea and/or metformin use. Since pramlintide is given as a mealtime subcutaneous injection, it mainly targets postprandial glycemic excursions. Although its effects on HbA 1C are modest and it often causes transient nausea, pramlintide has gained popularity as a result of its relatively few contraindications, minimal risk for hypoglycemia and potential for weight loss. This paper will review pramlintide s mechanisms of action, clinical efficacy in terms of achieving goal HbA 1C s and weight loss, safety and tolerability, patient satisfaction, and directions for future consideration. Amylin is a 37-amino acid polypeptide with a 6-amino acid ring structure that is co-secreted along with insulin by pancreatic β cells in response to a nutrient stimulus. 1 3 Like insulin, it downregulates Correspondence: Caroline Messer, Department of Endocrinology, Diabetes and Bone Disease, Mount Sinai School of Medicine, New York, New York 129, U.S.A. caroline.messer@mssm.edu Copyright in this article, its metadata, and any supplementary data is held by its author or authors. It is published under the Creative Commons Attribution By licence. For further information go to: The authors grant exclusive rights to all commercial reproduction and distribution to Libertas Academica. Commercial reproduction and distribution rights are reserved by Libertas Academica. No unauthorised commercial use permitted without express consent of Libertas Academica. Contact tom.hill@la-press.com for further information. Clinical Medicine: Therapeutics 29:
2 Messer and Green glucose levels. In healthy subjects, it is secreted in pulses every six to eight minutes. 4 However, amylin secretion appears to be diminished or absent in patients with type 1 and 2 diabetes (Fig. 1). 5 The severity of amylin deficiency closely coincides with the degree of insulin deficiency. 3 Native amylin is characterized as glue-like and unstable in solution. Therefore, native amylin was modified to form pramlintide, an injectable synthetic version of amylin. By replacing three amino acid residues ( 25 Ala, 28 Ser, and 29 Ser), pramlintide mimics amylin s physiologic properties in the form of a stable injectable product (Fig. 2). 6 8 lowers glucose through the same mechanisms as amylin: It slows gastric emptying, suppresses the postprandial rise of glucagon in patients with diabetes, and promotes satiety. 1,11 Gastric emptying occurs more rapidly in patients with type 2 diabetes when compared to controls. 12 This acceleration may be partially due to the decreased or absent amylin levels characteristic of diabetes. slows gastric emptying for both liquids and solids (Fig. 3A), thus limiting the rate at which nutrients enter circulation and decreasing postprandial glucose excursions. also suppresses the postprandial rise of glucagon. Glucagon is released by the alpha cells of the pancreas in response to hypoglycemia in order to stimulate hepatic glucose production. Postprandial levels of glucagon are abnormally elevated in type 1 and type 2 diabetes and cause both increased glycogenolysis and gluconeogenesis. 13,14 has been shown to significantly reduce postprandial glucagon excursions when compared to placebo. (Fig. 3B) 1,15 Finally, in patients with type 2 diabetes and in overweight patients without diabetes, a single pre-prandial injection of pramlintide has been shown to reduce food intake by 16%3%. treated patients experience increased levels of satiety when compared to controls (Fig. 3C). 16 The two pivotal studies involving pramlintide use in patients with type 1 diabetes were performed by Ratner et al. and Whitehouse et al. In a multicenter, double-blind, placebo-controlled trial, Ratner et al. A B Plasma amylin (pm) Plasma amylin (pm) Meals am 12 noon 5 pm 2 Meal Amylin Insulin Midnight Healthy subjects Type 2 diabetes using insulin Type 1 diabetes Plasma insulin (pm) Time after meal (min) Figure 1. A) 24 hour plasma insulin and amylin profi les in healthy subjects. B) Mean Amylin +/ standard deviation versus time after a meal. Amylin response is absent in type 1 diabetics and decreased in insulin-dependent type 2 diabetics Clinical Medicine: Therapeutics 29:1
3 A review of pramlintide in the management of diabetes Human amylin A T A T T A Q L N L N C R F V C H K S Amide S Y S S L A F T I G N N N T S V N G Amide ( 25,28,29Pro-h-amylin) A T A T T A Q L N L N C R F V C H K S S Y T T P P L I P G F N N N S V N G Figure 2. Amino Acid sequences of human amylin and the amylin analogue pramlintide. Reprinted with permission. 9 showed that pramlintide dosed TID or QID over one year led to A1C reductions in patients with type 1 diabetes of.29% (p.11) and.34% (p.1), respectively, compared to only a.4% reduction in a placebo group. 18 The proportion of test subjects who achieved a target A1C of 7% was 3 times higher than control subjects. Weight loss tended to occur more in obese patients than in patients at ideal body weight. Ratner et al. also demonstrated positive effects on glycemic control when a subset of patients with A1C values 8% were evaluated along with similar patients from other studies. 19 Whitehouse and colleagues conducted a multicenter, double-blinded, placebo-controlled trial analyzing the efficacy of adjunctive pramlintide on both glycemic and weight control in patients with type 1 diabetes. In a 52-week trial, they randomized patients with type 1 diabetes to receive premeal injections of placebo or 3 μg 6 μg of pramlintide in addition to existing insulin regimens. They found that the patients using pramlintide had a modest ( 1%) but sustained reduction in A1C (Fig. 4). 2 The target A1C of less than 7% was achieved in 25% of patients taking pramlintide versus only 11.3% in the control patients without an increased incidence of hypoglycemic events. Test subjects experienced weight loss while the insulin-only control group gained weight. The weight loss was significant from week 13 onward. In 26, Edelman et al. evaluated pramlintide s ability to facilitate weight loss in patients with type 1 diabetes. They published the results of a 29-week, randomized, double-blind, placebo-controlled trial in which 296 patients with type 1 diabetes were treated with pramlintide vs. placebo. They reported that pramlintide treatment led to a significant reduction in weight (p.1) despite equivalent HbA1C reductions relative to a placebo. 21 Hollander et al. and Ratner et al. investigated the role of pramlintide in the treatment of type 2 diabetes. Hollander et al. studied the effects of pramlintide in patients with type 2 diabetes on insulin with or without a sulfonylurea or metformin in a double-blind, placebo-controlled, parallel-group study. Patients receiving pramlintide 6 μg TID, pramlintide 9 μg BID, or pramlintide 12 μg BID were evaluated at 26 and 52 weeks for change in HbA 1C and body weight. They showed that 12 μg of twice daily pramlintide significantly reduced both HbA 1C and weight. In addition, 9.4% of the pramlintide 9 μg BID group and 12% of the pramlintide 12 μg BID group achieved a HbA 1C 7% compared to only 4.1% of placebo patients. Furthermore, 42.4% the pramlintide 9 μg BID group and 45.7% of the pramlintide 12 μg BID group compared to only 27.6% of placebo achieved a HbA 1C 8%. 22 Ratner et al. compared pramlintide to placebo in patients with type 2 diabetes and showed that test patients were more likely to have reductions in HbA 1C and body weight (Fig. 4). In a 52-week, double-blind, placebo-controlled, parallel group study, insulin-using patients were randomized to receive pramlintide 3, Clinical Medicine: Therapeutics 29:1 37
4 Messer and Green A Mean (±SE) Half-Emplying Time (minutes) * * 3 μg 6 μg B Mean (±SE) Plasma Glucagon (pg/ml) Type 1 Insulin Meal or 2 μgh infusion Time (min) Mean (±SE) Plasma Glucagon (pg/ml) Insulin Meal Type 2 or 1 μgh infusion Time (min) C Postprandial Satiety Quotient *.38 Figure 3. s 3 mechanisms of actions. A) increases gastric half-emptying compared with placebo (*indicates P.4). 11 B) reduces postprandial glucagon excursions for type 1 and type 2 diabetics compared with placebo. 1 C) signifi cantly increases postprandial satiety quotient (*indicates p =.29) compared with placebo. 16 Reprinted with permission , 15 μg TID or placebo TID. The end points included changes in HbA 1C, and body weight from baseline at weeks 13, 26, and 52 as well as changes in insulin use and proportion of patients attaining goal HbA 1C values. Significant reductions in HbA 1C were seen in the 75 and 15 μg groups at week 13 and 26. However, by week 52, the reduction in HbA 1C was only significant in the 15 μg group. The proportion of patients attaining a goal HbA 1C of 7% was 12.7%, 13.4%, 19.2% and 11.1% in the pramlintide 3, 75, 15 μg and placebo TID groups, respectively. The proportion of patients attaining a goal HbA 1C of 8% was 45.1%, 46.4%, 54% and 37.6% in the pramlintide 3, 75, 15 μg and placebo TID groups, respectively. All pramlintide patients had significant reductions in body weight at weeks 13, 26, and 52, while patients in the placebo group actually gained an average of 1 kg by 26 weeks. 23 Riddle et al. assessed the efficacy of pramlintide in 212 patients who were sub-optimally controlled on glargine insulin with or without oral antidiabetes agents. 24 Patients were randomized to receive 6 mcg or12 mcg of pramlintide or placebo BID or TID for sixteen weeks in addition to their preexisting diabetes regimens. The primary endpoints included the change in HbA 1C and a composite measure of overall diabetes control (including A1C 7% or reduction by at least.5%, body weight neutral, hypoglycemic events). Patients receiving pramlintide had a significant reduction in HbA 1C compared with 38 Clinical Medicine: Therapeutics 29:1
5 A review of pramlintide in the management of diabetes A Type 2 Diabetes Δ A1C (%) Δ Insulin Use (%) ΔWeight (Kg) Week 4 Week 13 Week 26 Week 4 Week 13 Week 26 Week 4 Week 13 Week * 4 placebo pramlintide B Type 1 Diabetes ΔA1C (%) ΔInsulin Use (%) ΔWeight (Kg) Week 4 Week 13 Week 26 * * * Week 4 Week 13 Week 26 * Week 4 Week 13 Week 26 * * * placebo pramlintide Figure 4. Results for combined pivotal studies with pramlintide in patients with type 1 and type 2 diabetes. The change in A1C, total daily insulin use and weight at 4, 13, and 26 weeks are expressed as mean ± SE, ITT observed. A) Patients with type 2 diabetes at 12 μg pramlintide BID (n = 292) versus placebo (n = 284), *p.1, p.1. B) Patients with type 1 diabetes, 3 6 μg doses TID and QID (n = 716) versus placebo (n = 538), *p.5, p.1, *p.1 combined data adapted from. 18,2,22,23 Reprinted with permission. 17 placebo (.7 vs..36, P.5). More pramlintide than placebo-treated patients achieved the composite end point (25 vs. 7%; P.1). Improvement in glycemic control was accompanied by progressive weight loss with pramlintide and weight gain with placebo ( 1.6 +/.3 kg vs /.3 kg; P.1). This study suggests that pramlintide may be a promising alternative to mealtime insulin in patients who desire weight loss and are not adequately controlled on basal insulin. should be injected subcutaneously in the abdominal area or thigh immediately before meals. should not be mixed with insulin or injected at the same site as insulin. 25 For safety purposes, it is recommended to be given before a meal containing 25 calories, and the usual preprandial insulin dose should be halved at first and then uptitrated as tolerated to minimize hypoglycemia. 258 In type 1 diabetes, several studies show that the rates of hypoglycemia are increased in pramlintide treated patients versus placebo. 191,29 However, pramlintide does not appear to reduce the glucagon response to hypoglycemia. In fact, one study showed that none of the counter-regulatory hormones triggered by hypoglycemia, i.e. catecholamines, growth hormone, cortisol, and glucagon, were attenuated by pramlintide. 3 Because pramlintide works in part by slowing gastric emptying, it may delay the absorption of oral medications. Therefore, oral medications should be taken either an hour before or two hours after an injection of pramlintide. Caution should also be used when patients are already receiving anticholinergics or agents that slow intestinal absorption, such as α-glucosidase inhibitors. Since nausea is more likely to be a problem in patients with gastroparesis, pramlintide is generally considered to be contraindicated in these patients. dosing does not need to be adjusted for the elderly or for patients with renal or hepatic impairment. However, there are no studies in dialysis patients and it has not yet been approved for use during pregnancy. It should not be used in patients who do not require insulin or are on basal insulin only. As of now, it is not approved for use with exenatide or Januvia. There are no reports to date of toxicity to major Clinical Medicine: Therapeutics 29:1 39
6 Messer and Green organs or any deleterious effects on the physical exam, hemodynamics, electrocardiograms, or laboratory tests. The starting dose in type 1 diabetes is 15 μg, and this dose may be uptitrated in increments of 15 μg every three to seven days for a goal of 6 μg. In patients with type 2 diabetes, the initial dose is higher at 6 μg, and the target dose is 12 μg. Therapy is started at these lower doses to reduce the incidence of nausea. A small subset of patients may have intolerable nausea despite receiving the lowest doses. In most patients, however, the nausea, vomiting, and anorexia tend to resolve following the first 4 8 weeks of therapy. There have been some potential safety concerns involving proper dosing of pramlintide. Symlin has a concentration of 6 mcg/ml solution. When pramlintide was first introduced to the market, it was labeled as a.6 mg/ml solution. This was a possible source of confusion for patients since pramlintide is dosed in micrograms rather than milligrams. In addition, patients may be confused by the instructions to withdraw the medication in units using an insulin syringe. The product is currently labeled as containing 6 mcg/ml, and the advent of the SymlinPen has helped further simplify dosing. In 27, Amylin Pharmaceuticals, Inc. developed two new prefilled pen-injector devices called the SymlinPen 12 and the SymlinPen 6. The SymlinPen 12 can deliver 6 or 12 micrograms of pramlintide per dose, while the SymlinPen 6 can deliver 15, 3, 45, or 6 micrograms of pramlintide per dose. Both pens can be stored at room temperature (though not to exceed 86 F) once they are in use. SymlinPen 6 is formulated as a 1 mcg/ml solution, and each box contains two 1.5 ml Syringes. The wholesale price for one box is $ SymlinPen 12 is formulated as a 1 mcg/ml solution, and each box contains two 2.7 ml Syringes. The wholesale price for one box is $ (Amylin Customer Support Center, ). Marrero et al. conducted a survey of patient satisfaction in those patients receiving insulin only versus insulin plus pramlintide after 29 weeks. 29 Patients in the test group felt that pramlintide helped control weight gain and appetite as well as facilitate activities of daily living. They believed that the benefits of pramlintide outweighed the downside of the extra injections daily and would recommend this therapy to other patients. In light of the patient satisfaction described above, there is a potential niche for pramlintide among insulin-dependent patients with type 1 and 2 diabetes who are either unable to achieve euglycemic states with insulin alone or are frustrated by insulin-induced weight gain. Recently, Heptulla et al. demonstrated the role of continuous subcutaneous replacement of amylin and insulin for a 24-hour period on glucose control in adolescents with type 1 diabetes. They hypothesized that pre and postprandial amylin replacement would normalize blood glucose concentrations. Their study compared continuous subcutaneous insulin monotherapy (part A) with continuous subcutaneous insulin and pramlintide infusions (part B). In part B, the prandial insulin boluses were reduced by 2%. The basal and prandial pramlintide were administered simultaneously using another pump, and the boluses were given as dual-wave boluses with 7% of the dose given immediately and 3% over the next hour. The patients on dual therapy showed a 26% reduction in postprandial hyperglycemia compared to the patients on insulin monotherapy. 31 Additional potential roles for pramlintide include monotherapy or adjunct therapy to other medications for weight loss. In a recent clinical observation study of overweight and obese subjects, the coadministration of metreleptin and pramlintide acetate for 2 weeks elicited significantly more weight loss (approximately 13%) than either treatment alone. 32 In a randomized 24-week single-blind study, the combination of pramlintide with sibutramine or phentermine led to a significant increase in weight loss (approximately 11 kg) when compared with pramlintide monotherapy (approximately 4 kg). 33 In summary, pramlintide is an amylin analog that plays a role in adjunct treatment of both type 1 and type 2 diabetes. Although it has only a modest effect on HbA 1C reduction, pramlintide does appear to lessen post-prandial glycemic excursions and has a favorable effect on weight. The main limitation in the use of pramlintide is the necessity of additional subcutaneous injections in individuals who are already injecting upwards of four times daily. However, Riddle et al. showed that pramlintide may also potentially be used as an alternative to mealtime insulin in patients who are not adequately controlled on basal insulin. As pump technology improves and allows for injection of both insulin and pramlintide, one might predict that pramlintide will become even more appealing, 31 Clinical Medicine: Therapeutics 29:1
7 A review of pramlintide in the management of diabetes especially in individuals with type 1 diabetes. Future considerations are likely to include the use of continuous subcutaneous pramlintide as well as dual-wave boluses of pramlintide to combat early postprandial hypoglycemia and late postprandial hyperglycemia. At that point, it will be important to conduct additional studies to examine both the long-term effects of pramlintide and also the effect of this medication on the development of diabetes-related complications. Other potential uses of pramlintide, including its potential role as a weight loss agent, continue to require further study. Disclosure The authors report no conflicts of interest. References 1. The DCCT Research Group. Weight gain associated with intensive therapy in the diabetes control and complications trial. Diabetes Care. 1988;11(7): Uwaifo GI, Ratner RE. Novel pharmacologic agents for type 2 diabetes. Endocrinol Metab Clin North Am. 25;34(1): Young A. Tissue expression and secretion of amylin. Adv Pharmacol. 25;52: Juhl CB, Porksen N, Sturis J, et al. High-frequency oscillations in circulating amylin concentrations in healthy humans. Am J Physiol Endocrinol Metab. 2;278(3):E Baron AD, Kim D, Weyer C. Novel peptides under development for the treatment of type 1 and type 2 diabetes mellitus. Curr Drug Targets Immune Endocr Metabol Disord. 22;2(1): Gedulin BJDGD. Amylin inhibition of arginine-induced glucagon secretion: comparison with glucagon like peptide-1 (7 36)-amide (GLP-1). Diabetologia. 1996;39(Suppl 1):A Thompson RG, Pearson L, Schoenfeld SL, Kolterman OG., a synthetic analog of human amylin, improves the metabolic profile of patients with type 2 diabetes using insulin. The in Type 2 Diabetes Group. Diabetes Care. 1998;21(6): Vella A, Lee JS, Camilleri M, et al. Effects of pramlintide, an amylin analogue, on gastric emptying in type 1 and 2 diabetes mellitus. Neurogastroenterol Motil. 22;14(2): Buse JB, Weyer C, Maggs DG. Amylin replacement with pramlintide in type 1 and type 2 diabetes: A physiological approach to overcome barriers with insulin therapy. Clinical Diabetes. 22;2: Fineman MS, Koda JE, Shen LZ, et al. The human amylin analog, pramlintide, corrects postprandial hyperglucagonemia in patients with type 1 diabetes. Metabolism. 22b;51(5): Kong MF, Stubbs TA, King P, et al. The effect of single doses of pramlintide on gastric emptying of two meals in men with IDDM. Diabetologia. 1998;41(5): Schvarcz E, Palmer M, Aman J, Horowitz M, Stridsberg M, Berne C. Physiological hyperglycemia slows gastric emptying in normal subjects and patients with insulin-dependent diabetes mellitus. Gastroenterology. 1997;113(1): Unger RH, Aguilar-Parada E, Muller WA, Eisentraut AM. Studies of pancreatic alpha cell function in normal and diabetic subjects. J Clin Invest. 197;49(4): Unger RH, Orci L. The role of glucagon in the endogenous hyperglycemia of diabetes mellitus. Annu Rev Med. 1977;28: Fineman M, Weyer C, Maggs DG, Strobel S, Kolterman OG. The human amylin analog, pramlintide, reduces postprandial hyperglucagonemia in patients with type 2 diabetes mellitus. Horm Metab Res. 22a; 34(9): Chapman I, Parker B, Doran S, et al. Effect of pramlintide on satiety and food intake in obese subjects and subjects with type 2 diabetes. Diabetologia. 25;48(5): Pullman J, Darsow T, Frias JP. in the management of insulin-using patients with type 2 and type 1 diabetes. Vasc Health Risk Manag. 26;2(3): Ratner RE, Dickey R, Fineman M, et al. Amylin replacement with pramlintide as an adjunct to insulin therapy improves long-term glycaemic and weight control in Type 1 diabetes mellitus: a 1-year, randomized controlled trial. Diabet Med. 24;21(11): Ratner R, Whitehouse F, Fineman MS, et al. Adjunctive therapy with pramlintide lowers HbA1c without concomitant weight gain and increased risk of severe hypoglycemia in patients with type 1 diabetes approaching glycemic targets. Exp Clin Endocrinol Diabetes. 25;113(4): Whitehouse F, Kruger DF, Fineman M, et al. A randomized study and open-label extension evaluating the long-term efficacy of pramlintide as an adjunct to insulin therapy in type 1 diabetes. Diabetes Care. 22;25(4): Edelman S, Garg S, Frias J, et al. A double-blind, placebo-controlled trial assessing pramlintide treatment in the setting of intensive insulin therapy in type 1 diabetes. Diabetes Care. 26;29(1): Hollander PA, Levy P, Fineman MS, et al. as an adjunct to insulin therapy improves long-term glycemic and weight control in patients with type 2 diabetes: a 1-year randomized controlled trial. Diabetes Care. 23;26(3): Ratner RE, Want LL, Fineman MS, et al. Adjunctive therapy with the amylin analogue pramlintide leads to a combined improvement in glycemic and weight control in insulin-treated subjects with type 2 diabetes. Diabetes Technol Ther. 22;4(1): Riddle M, Frias J, Zhang B, et al. improved glycemic control and reduced weight in patients with type 2 diabetes using basal insulin. Diabetes Care. 27;3(11): Schmitz O, Brock B, Rungby J. Amylin agonists: a novel approach in the treatment of diabetes. Diabetes. 24;53(3):S233 S Creutzfeldt W. The [pre-] history of the incretin concept. Regul Pept. 25;128(2): Maggs DG, Fineman M, Kornstein J, et al. reduces postprandial glucose excursions when added to insulin lispro in subjects with type 2 diabetes: a dose-timing study. Diabetes Metab Res Rev. 24;2(1): Weyer C, Gottlieb A, Kim DD, et al. reduces postprandial glucose excursions when added to regular insulin or insulin lispro in subjects with type 1 diabetes: a dose-timing study. Diabetes Care. 23;26(11): Marrero DG, Crean J, Zhang B, et al. Effect of adjunctive pramlintide treatment on treatment satisfaction in patients with type 1 diabetes. Diabetes Care. 27;3(2): Amiel SA, Heller SR, Macdonald IA, et al. The effect of pramlintide on hormonal, metabolic or symptomatic responses to insulin-induced hypoglycaemia in patients with type 1 diabetes. Diabetes Obes Metab. 25;7(5): Heptulla RA, Rodriguez LM, Mason KJ, Haymond MW. Twenty-four hour Simultaneous Subcutaneous Basal-Bolus Administration of Insulin and Amylin in Adolescents with Type 1 Diabetes Decreases Post- Prandial Hyperglycemia. J Clin Endocrinol Metab Roth JD, Maier H, Chen S, Roland BL. Implications of amylin receptor agonism: integrated neurohormonal mechanisms and therapeutic applications. Arch Neurol. 29;66(3): Aronne LJ, Halseth A, Burns C, Porter L, Shen L. Enhanced weight loss following co-administration of pramlintide with sibutramine or phentermine in obese subjects. Diabetes. 28;57(suppl 1):A3 1. Clinical Medicine: Therapeutics 29:1 311
1.* Dosage/Administration
Pramlintide (Symlin ) [Developed, February 2006; Revised, May 2006; January 2010; December 2011; October 2013] MEDICAID DRUG USE REVIEW CRITERIA FOR OUTPATIENT USE Information on indications for use or
More informationChanging Diabetes: The time is now!
Midwest Cardiovascular Research Foundation Welcomes DANITA HARRISON, ARNP Ms. Harrison discloses speaking relationships with Lilly, Novo Nordisk and Pfizer. Changing Diabetes: The time is now! Danita Harrison
More informationPramlintide & Weight. Diane M Karl MD. The Endocrine Clinic & Oregon Health & Science University Portland, Oregon
Pramlintide & Weight Diane M Karl MD The Endocrine Clinic & Oregon Health & Science University Portland, Oregon Conflict of Interest Speakers Bureau: Amylin Pharmaceuticals Consultant: sanofi-aventis Grant
More informationGLP-1 agonists. Ian Gallen Consultant Community Diabetologist Royal Berkshire Hospital Reading UK
GLP-1 agonists Ian Gallen Consultant Community Diabetologist Royal Berkshire Hospital Reading UK What do GLP-1 agonists do? Physiology of postprandial glucose regulation Meal ❶ ❷ Insulin Rising plasma
More informationDrug Update. Pramlintide. Pitale S U, Sahasrabuddhe A V. Chemical Structure :
Drug Update Vidarbha Journal of Internal Medicine Volume 21 July 201 Pramlintide 1 2 Pitale S U, Sahasrabuddhe A V ABSTRACT Amylin is a second beta-cell hormone that is co-secreted with insulin, in response
More informationData from an epidemiologic analysis of
CLINICAL TRIAL RESULTS OF GLP-1 RELATED AGENTS: THE EARLY EVIDENCE Lawrence Blonde, MD, FACP, FACE ABSTRACT Although it is well known that lowering A 1c (also known as glycated hemoglobin) is associated
More informationPractical Strategies for the Clinical Use of Incretin Mimetics CME/CE. CME/CE Released: 09/15/2009; Valid for credit through 09/15/2010
Practical Strategies for the Clinical Use of Incretin Mimetics CME/CE Robert R. Henry, MD Authors and Disclosures CME/CE Released: 09/15/2009; Valid for credit through 09/15/2010 Introduction Type 2 diabetes
More informationManagement of Type 2 Diabetes
Management of Type 2 Diabetes Pathophysiology Insulin resistance and relative insulin deficiency/ defective secretion Not immune mediated No evidence of β cell destruction Increased risk with age, obesity
More informationChief of Endocrinology East Orange General Hospital
Targeting the Incretins System: Can it Improve Our Ability to Treat Type 2 Diabetes? Darshi Sunderam, MD Darshi Sunderam, MD Chief of Endocrinology East Orange General Hospital Age-adjusted Percentage
More informationGLP-1 (glucagon-like peptide-1) Agonists (Byetta, Bydureon, Tanzeum, Trulicity, Victoza ) Step Therapy and Quantity Limit Criteria Program Summary
OBJECTIVE The intent of the GLP-1 (glucagon-like peptide-1) s (Byetta/exenatide, Bydureon/ exenatide extended-release, Tanzeum/albiglutide, Trulicity/dulaglutide, and Victoza/liraglutide) Step Therapy
More informationAdlyxin. (lixisenatide) New Product Slideshow
Adlyxin (lixisenatide) New Product Slideshow Introduction Brand name: Adlyxin Generic name: Lixisenatide Pharmacological class: Glucagon-like peptide-1 (GLP-1) receptor agonist Strength and Formulation:
More information22 Emerging Therapies for
22 Emerging Therapies for Treatment of Type 2 Diabetes Siddharth N Shah Abstract: The prevalence of Diabetes is progressively increasing world-wide and the growth of the disease in our country is phenomenal.
More informationInitiating Injectable Therapy in Type 2 Diabetes
Initiating Injectable Therapy in Type 2 Diabetes David Doriguzzi, PA C Learning Objectives To understand current Diabetes treatment guidelines To understand how injectable medications fit into current
More informationMultiple Factors Should Be Considered When Setting a Glycemic Goal
Multiple Facts Should Be Considered When Setting a Glycemic Goal Patient attitude and expected treatment effts Risks potentially associated with hypoglycemia, other adverse events Disease duration Me stringent
More informationModulating the Incretin System: A New Therapeutic Strategy for Type 2 Diabetes
Modulating the Incretin System: A New Therapeutic Strategy for Type 2 Diabetes Geneva Clark Briggs, PharmD, BCPS Adjunct Professor at University of Appalachia College of Pharmacy Clinical Associate, Medical
More informationNon-insulin treatment in Type 1 DM Sang Yong Kim
Non-insulin treatment in Type 1 DM Sang Yong Kim Chosun University Hospital Conflict of interest disclosure None Committee of Scientific Affairs Committee of Scientific Affairs Insulin therapy is the mainstay
More informationIt is estimated that approximately 20.8 million Americans
FORMULARY MANAGEMENT Managed Care Perspective on Three New Agents for Type 2 Diabetes Shawna VanDeKoppel, PharmD; Hae Mi Choe, PharmD, CDE; and Burgunda V. Sweet, PharmD, FASHP ABSTRACT BACKGROUND: Despite
More informationDisclosure. Learning Objectives. Case. Diabetes Update: Incretin Agents in Diabetes-When to Use Them? I have no disclosures to declare
Disclosure Diabetes Update: Incretin Agents in Diabetes-When to Use Them? I have no disclosures to declare Spring Therapeutics Update 2011 CSHP BC Branch Anar Dossa BScPharm Pharm D CDE April 20, 2011
More informationGLUCAGON LIKE PEPTIDE (GLP) 1 AGONISTS FOR THE TREATMENT OF TYPE 2 DIABETES, WEIGHT CONTROL AND CARDIOVASCULAR PROTECTION.
GLUCAGON LIKE PEPTIDE (GLP) 1 AGONISTS FOR THE TREATMENT OF TYPE 2 DIABETES, WEIGHT CONTROL AND CARDIOVASCULAR PROTECTION. Patricia Garnica MS, ANP-BC, CDE, CDTC Inpatient Diabetes Nurse Practitioner North
More informationINJECTABLE THERAPY FOR THE TREATMENT OF DIABETES
INJECTABLE THERAPY FOR THE TREATMENT OF DIABETES ARSHNA SANGHRAJKA DIABETES SPECIALIST PRESCRIBING PHARMACIST OBJECTIVES EXPLORE THE TYPES OF INSULIN AND INJECTABLE DIABETES TREATMENTS AND DEVICES AVAILABLE
More informationApproaches to Addressing Incretin Deficiency. Non-Insulin Injectable Agents. Incretin Mimetics. Exendin-4 in the Gila Monster
Non-Insulin Injectable Agents Approaches to Addressing Incretin Deficiency Longer-acting analogs? (Incretin mimetics) GLP-1 Analogs Inhibition of inactivation? (Incretin enhancers) DPP-4 Inhibitors Drucker
More informationGLP-1 receptor agonists for type 2 diabetes currently available in the U.S.
GLP-1 receptor agonists for type 2 diabetes currently available in the U.S. GLP-1 agonists are a class of antidiabetic agents that mimic the actions of the glucagon-like peptide. GLP-1 is one of several
More informationXultophy 100/3.6. (insulin degludec, liraglutide) New Product Slideshow
Xultophy 100/3.6 (insulin degludec, liraglutide) New Product Slideshow Introduction Brand name: Xultophy Generic name: Insulin degludec, liraglutide Pharmacological class: Human insulin analog + glucagon-like
More informationSoliqua 100/33. (insulin glargine, lixisenatide) New Product Slideshow
Soliqua 100/33 (insulin glargine, lixisenatide) New Product Slideshow Introduction Brand name: Soliqua 100/33 Generic name: Insulin glargine (rdna origin), lixisenatide Pharmacological class: Human insulin
More informationSociety for Ambulatory Anesthesia Consensus Statement on Perioperative Blood Glucose Management in Diabetic Patients Undergoing Ambulatory Surgery
Society for Ambulatory Anesthesia Consensus Statement on Perioperative Blood Glucose Management in Diabetic Patients Undergoing Ambulatory Surgery Girish P. Joshi, MB BS, MD, FFARCSI Anesthesia & Analgesia
More informationWhat s New on the Horizon: Diabetes Medication Update
What s New on the Horizon: Diabetes Medication Update Outline of Talk Newly released and upcoming medications: the incretins, DPP-IV inhibitors, and what s coming Revised ADA/EASD and AACE guidelines:
More informationPancreatic b-cell Dysfunction in Type 2 Diabetes ZIAD KAHWASH, M.D. Insulin resistance: Defects in Insulin Signaling
Plasma insulin (mu/ml) ZIAD KAHWASH, M.D. resistance: Defects in Signaling Increased glucose production Glucose Insufficient glucose disposal X Liver glucagon insulin Pancreas Peripheral tissues (skeletal
More informationDrugs used in Diabetes. Dr Andrew Smith
Drugs used in Diabetes Dr Andrew Smith Plan Introduction Insulin Sensitising Drugs: Metformin Glitazones Insulin Secretagogues: Sulphonylureas Meglitinides Others: Acarbose Incretins Amylin Analogues Damaglifozin
More informationSitagliptin: first DPP-4 inhibitor to treat type 2 diabetes Steve Chaplin MSc, MRPharmS and Andrew Krentz MD, FRCP
Sitagliptin: first DPP-4 inhibitor to treat type 2 diabetes Steve Chaplin MSc, MRPharmS and Andrew Krentz MD, FRCP KEY POINTS sitagliptin (Januvia) is a DPP-4 inhibitor that blocks the breakdown of the
More informationDiabetes Mellitus Type 2 Evidence-Based Drivers
This module is supported by an unrestricted educational grant by Aventis Pharmaceuticals Education Center. Copyright 2003 1 Diabetes Mellitus Type 2 Evidence-Based Drivers Driver One: Reducing blood glucose
More informationFrancesca Porcellati
XX Congresso Nazionale AMD Razionali e Benefici dell Aggiunta del GLP-1 RA Short-Acting all Insulina Basale Francesca Porcellati Dipartimento di Medicina Interna, Sezione di Medicina Interna, Endocrinologia
More informationWhat s New on the Horizon: Diabetes Medication Update. Michael Shannon, MD Providence Endocrinology, Olympia WA
What s New on the Horizon: Diabetes Medication Update Michael Shannon, MD Providence Endocrinology, Olympia WA 1 Outline of Talk Newly released and upcoming medications: the incretins, DPP-IV inhibitors,
More informationDiabetes: Three Core Deficits
Diabetes: Three Core Deficits Fat Cell Dysfunction Impaired Incretin Function Impaired Appetite Suppression Obesity and Insulin Resistance in Muscle and Liver Hyperglycemia Impaired Insulin Secretion Islet
More informationAgenda. Indications Different insulin preparations Insulin initiation Insulin intensification
Insulin Therapy F. Hosseinpanah Obesity Research Center Research Institute for Endocrine sciences Shahid Beheshti University of Medical Sciences November 11, 2017 Agenda Indications Different insulin preparations
More informationJulie White, MS Administrative Director Boston University School of Medicine Continuing Medical Education
MENTOR QI Diabetes Performance Improvement Initiative, Getting Patients to Goal in Glycemic Control: Current Data Julie White, MS Administrative Director Boston University School of Medicine Continuing
More informationAchieving and maintaining good glycemic control is an
Glycemic Efficacy, Weight Effects, and Safety of Once-Weekly Glucagon-Like Peptide-1 Receptor Agonists Yehuda Handelsman, MD, FACP, FNLA, FASPC, MACE; Kathleen Wyne, MD, PhD, FACE, FNLA; Anthony Cannon,
More informationRole of incretins in the treatment of type 2 diabetes
Role of incretins in the treatment of type 2 diabetes Jens Juul Holst Department of Medical Physiology Panum Institute University of Copenhagen Denmark Diabetes & Obesity Spanish Society of Internal Medicine
More informationInitiation and Titration of Insulin in Diabetes Mellitus Type 2
Initiation and Titration of Insulin in Diabetes Mellitus Type 2 Greg Doelle MD, MS April 6, 2016 Disclosure I have no actual or potential conflicts of interest in relation to the content of this lecture.
More informationFARXIGA (dapagliflozin) Jardiance (empagliflozin) tablets. Synjardy (empagliflozin and metformin hydrochloride) tablets. GLUCOPHAGE* (metformin)
Type 2 Medications Drug Class How It Works Brand and Generic Names Manufacturers Usual Starting Dose The kidneys filter sugar and either absorb it back into your body for energy or remove it through your
More informationEarly treatment for patients with Type 2 Diabetes
Israel Society of Internal Medicine Kibutz Hagoshrim, June 22, 2012 Early treatment for patients with Type 2 Diabetes Eduard Montanya Hospital Universitari Bellvitge-IDIBELL CIBERDEM University of Barcelona
More informationInsulin Initiation and Intensification. Disclosure. Objectives
Insulin Initiation and Intensification Neil Skolnik, M.D. Associate Director Family Medicine Residency Program Abington Memorial Hospital Professor of Family and Community Medicine Temple University School
More informationCase Report Off-Label Use of Liraglutide in the Management of a Pediatric Patient with Type 2 Diabetes Mellitus
Case Reports in Pediatrics Volume 2013, Article ID 703925, 4 pages http://dx.doi.org/10.1155/2013/703925 Case Report Off-Label Use of Liraglutide in the Management of a Pediatric Patient with Type 2 Diabetes
More informationScottish Medicines Consortium
Scottish Medicines Consortium liraglutide 6mg/mL prefilled pen for injection (3mL) (Victoza ) Novo Nordisk Ltd. No. (585/09) 06 November 2009 The Scottish Medicines Consortium (SMC) has completed its assessment
More informationTreatment Options for Diabetes: An Update
Treatment Options for Diabetes: An Update A/Prof. Marg McGill Manager, Diabetes Centre Dr. Ted Wu Staff Specialist Endocrinologist Diabetes Centre Centre of Health Professional Education Education Provider
More informationComprehensive Diabetes Treatment
Comprehensive Diabetes Treatment Joshua L. Cohen, M.D., F.A.C.P. Professor of Medicine Interim Director, Division of Endocrinology & Metabolism The George Washington University School of Medicine Diabetes
More informationEXENATIDE (BYETTA ) PROTOCOL, 5mcg and 10mcg SC injection pre-filled pens
EXENATIDE (BYETTA ) PROTOCOL, 5mcg and 10mcg SC injection pre-filled pens This document should be read in conjunction with the current Summary of Product Characteristics http://www.medicines.org.uk 1.
More informationVICTOSA and Renal impairment DR.R.S.SAJAD
VICTOSA and Renal impairment DR.R.S.SAJAD February 2019 Main effect of GLP-1 is : Stimulating glucose dependent insulin release from the pancreatic islets. Slow gastric emptying Inhibit inappropriate
More informationCURRENT STATEGIES IN DIABETES MELLITUS DIABETES. Recommendations for Adults CURRENT STRATEGIES IN DIABETES MELLITUS. Diabetes Mellitus: U.S.
CURRENT STATEGIES IN DIABETES MELLITUS Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Diabetes Mellitus: U.S. Impact ~1 Million Type 1 DIABETES 16.7 Million IFG (8.3%) 12.3
More informationNormal Fuel Metabolism Five phases of fuel homeostasis have been described A. Phase I is the fed state (0 to 3.9 hours after meal/food consumption),
Normal Fuel Metabolism Five phases of fuel homeostasis have been described A. Phase I is the fed state (0 to 3.9 hours after meal/food consumption), in which blood glucose predominantly originates from
More informationUpdate on Diabetes Mellitus
Update on Diabetes Mellitus Treatment: Targeting the Incretin System Overview Underlying defects with Type 2 diabetes Importance of managing postprandial glucose control Amylin Incretin Hormones New therapies
More informationProfessor Rudy Bilous James Cook University Hospital
Professor Rudy Bilous James Cook University Hospital Rate per 100 patient years Rate per 100 patient years 16 Risk of retinopathy progression 16 Risk of developing microalbuminuria 12 12 8 8 4 0 0 5 6
More informationObesity, Insulin Resistance, Metabolic Syndrome, and the Natural History of Type 2 Diabetes
Obesity, Insulin Resistance, Metabolic Syndrome, and the Natural History of Type 2 Diabetes Genetics, environment, and lifestyle (obesity, inactivity, poor diet) Impaired fasting glucose Decreased β-cell
More informationManagement of Type 2 Diabetes. Why Do We Bother to Achieve Good Control in DM2. Insulin Secretion. The Importance of BP and Glucose Control
Insulin Secretion Management of Type 2 Diabetes DG van Zyl Why Do We Bother to Achieve Good Control in DM2 % reduction 0-5 -10-15 -20-25 -30-35 -40 The Importance of BP and Glucose Control Effects of tight
More informationNew and Emerging Therapies for Type 2 DM
Dale Clayton MHSc, MD, FRCPC Dalhousie University/Capital Health April 28, 2011 New and Emerging Therapies for Type 2 DM The science of today, is the technology of tomorrow. Edward Teller American Physicist
More informationΑναγκαιότητα και τρόπος ρύθμισης του διαβήτη στους νοσηλευόμενους ασθενείς
Αναγκαιότητα και τρόπος ρύθμισης του διαβήτη στους νοσηλευόμενους ασθενείς Αναστασία Θανοπούλου Επίκουρη Καθηγήτρια Β Παθολογικής Κλινικής Πανεπιστημίου Αθηνών Διαβητολογικό Κέντρο, Ιπποκράτειο Νοσοκομείο
More informationComparative Effectiveness, Safety, and Indications of Insulin Analogues in Premixed Formulations for Adults With Type 2 Diabetes Executive Summary
Number 14 Effective Health Care Comparative Effectiveness, Safety, and Indications of Insulin Analogues in Premixed Formulations for Adults With Type 2 Diabetes Executive Summary Background and Key Questions
More informationReviewing Diabetes Guidelines. Newsletter compiled by Danny Jaek, Pharm.D. Candidate
Reviewing Diabetes Guidelines Newsletter compiled by Danny Jaek, Pharm.D. Candidate AL AS KA N AT IV E DI AB ET ES TE A M Volume 6, Issue 1 Spring 2011 Dia bet es Dis pat ch There are nearly 24 million
More informationOBJECTIVES 4/7/2014. Diabetes Update Overview of the Diabetes Epidemic in the United States. ISHP Annual Spring Meeting
Diabetes Update 2014 ISHP Annual Spring Meeting Hayley Miller MD April 13, 2014 OBJECTIVES Review diabetes guidelines. Understand diabetes management targets. Discuss current therapeutic strategies. Overview
More informationMOA: Long acting glucagon-like peptide 1 receptor agonist
Alexandria Rydz MOA: Long acting glucagon-like peptide 1 receptor agonist Increases glucose dependent insulin secretion Decreases inappropriate glucagon secretion Increases β- cell growth and replication
More informationModulating the Incretin System: A New Therapeutic Strategy for Type 2 Diabetes. Overview. Prevalence of Overweight in the U.S.
Modulating the Incretin System: A New Therapeutic Strategy for Type 2 Diabetes Geneva Clark Briggs, PharmD, BCPS Overview Underlying defects with Type 2 diabetes Importance of managing postprandial glucose
More informationConsidering Pramlintide Therapy for Postprandial Blood Glucose Control
Considering Pramlintide Therapy for Postprandial Blood Glucose Control Belinda P. Childs, ARNP, MN, BC-ADM, CDE; Nicole C. Kesty, PhD; Eric Klein, MD; Richard Rubin, PhD, CDE; and Allison Wick, MSN, ARNP,
More informationDiabetes: What is the scope of the problem?
Diabetes: What is the scope of the problem? Elizabeth R. Seaquist MD Division of Endocrinology and Diabetes Department of Medicine Director, General Clinical Research Center Pennock Family Chair in Diabetes
More informationINSULIN IN THE OBESE PATIENT JACQUELINE THOMPSON RN, MAS, CDE SYSTEM DIRECTOR, DIABETES SERVICE LINE SHARP HEALTHCARE
INSULIN IN THE OBESE PATIENT JACQUELINE THOMPSON RN, MAS, CDE SYSTEM DIRECTOR, DIABETES SERVICE LINE SHARP HEALTHCARE OBJECTIVES DESCRIBE INSULIN, INCLUDING WHERE IT COMES FROM AND WHAT IT DOES STATE THAT
More informationNewer Drugs in the Management of Type 2 Diabetes Mellitus
Newer Drugs in the Management of Type 2 Diabetes Mellitus Dr. C. Dinesh M. Naidu Professor of Pharmacology, Kamineni Institute of Medical Sciences, Narketpally. 1 Presentation Outline Introduction Pathogenesis
More informationABSTRACT INTRODUCTION
/, 2017, Vol. 8, (No. 39), pp: 66504-66515 Efficacy and safety of pramlintide injection adjunct to insulin therapy in patients with type 1 diabetes mellitus: a systematic review and meta-analysis Yong-Chao
More informationPharmacotherapy IV: Liraglutide for Chronic Weight Management SARAH CAWSEY MD, FRCPC 2 ND ANNUAL OBESITY UPDATE SEPTEMBER 22, 2018
Pharmacotherapy IV: Liraglutide for Chronic Weight Management SARAH CAWSEY MD, FRCPC 2 ND ANNUAL OBESITY UPDATE SEPTEMBER 22, 2018 Disclosures Faculty Assistant Clinical Professor, Department of Medicine,
More informationPROCEEDINGS CLINICAL RESEARCH AND EXPERIENCE WITH INCRETIN-BASED THERAPIES * Vivian A. Fonseca, MD, FRCP ABSTRACT
CLINICAL RESEARCH AND EXPERIENCE WITH INCRETIN-BASED THERAPIES Vivian A. Fonseca, MD, FRCP ABSTRACT Despite proven lifestyle recommendations and the availability of a range of oral antidiabetic agents,
More informationOptimizing Treatment Strategies to Improve Patient Outcomes in the Management of Type 2 Diabetes
Optimizing Treatment Strategies to Improve Patient Outcomes in the Management of Type 2 Diabetes Philip Raskin, MD Professor of Medicine The University of Texas, Southwestern Medical Center NAMCP Spring
More informationExenatide Treatment for 6 Months Improves Insulin Sensitivity in Adults With Type 1 Diabetes
666 Diabetes Care Volume 37, March 2014 CLIN CARE/EDUCATION/NUTRITION/PSYCHOSOCIAL Exenatide Treatment for 6 Months Improves Insulin Sensitivity in Adults With Type 1 Diabetes Gayatri Sarkar, 1 May Alattar,
More informationThis program applies to Commercial, GenPlus and Health Insurance Marketplace formularies.
OBJECTIVE The intent of the GLP-1 (glucagon-like peptide-1) Agonists [Adlyxin (lixisenatide), Byetta (exenatide), Bydureon (exenatide extended-release), Tanzeum (albiglutide), Trulicity (dulaglutide),
More informationGLP 1 agonists Winning the Losing Battle. Dr Bernard SAMIA. KCS Congress: Impact through collaboration
GLP 1 agonists Winning the Losing Battle Dr Bernard SAMIA KCS Congress: Impact through collaboration CONTACT: Tel. +254 735 833 803 Email: kcardiacs@gmail.com Web: www.kenyacardiacs.org Disclosures I have
More informationA New Therapeutic Strategey for Type II Diabetes: Update 2008
Live, One Hour Webinar A New Therapeutic Strategey for Type II Diabetes: Update 2008 Geneva Clark Briggs, PharmD, BCPS Adjunct Professor at University of Appalachia College of Pharmacy in Grundy, Virginia.
More informationInjecting Insulin into Out Patient Practice
Injecting Insulin into Out Patient Practice Kathleen Colleran, MD Associate Professor UNMHSC 4/22/10 Overview Natural history of Type 2 diabetes Reasons clinicians are reluctant to start insulin therapy
More informationScope. History. History. Incretins. Incretin-based Therapy and DPP-4 Inhibitors
Plasma Glucose (mg/dl) Plasma Insulin (pmol/l) Incretin-based Therapy and Inhibitors Scope Mechanism of action ผศ.ดร.นพ.ว ระเดช พ ศประเสร ฐ สาขาว ชาโภชนว ทยาคล น ก ภาคว ชาอาย รศาสตร คณะแพทยศาสตร มหาว ทยาล
More informationSoliqua (insulin glargine and lixisenatide), Xultophy (insulin degludec and liraglutide)
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.30.48 Subject: Insulin GLP-1 Combinations Page: 1 of 5 Last Review Date: September 15, 2017 Insulin GLP-1
More informationIncretin-based Therapies for Type 2 Diabetes Comparisons Between Glucagon-like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors
Incretin-based Therapies for Type 2 Diabetes Comparisons Between Glucagon-like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors Timothy Bailey, MD, FACE, CPI Director, AMCR Institute,
More informationType II Diabetes Improving Blood Sugar Control. Geneva Clark Briggs, Pharm.D., BCPS
Type II Diabetes Improving Blood Sugar Control Geneva Clark Briggs, Pharm.D., BCPS Overview Importance of glucose control State of control Review available therapies Helping patients achieve control The
More informationTimely!Insulinization In!Type!2! Diabetes,!When!and!How
Timely!Insulinization In!Type!2! Diabetes,!When!and!How, FACP, FACE, CDE Professor of Internal Medicine UT Southwestern Medical Center Dallas, Texas Current Control and Targets 1 Treatment Guidelines for
More information28 Regulation of Fasting and Post-
28 Regulation of Fasting and Post- Prandial Glucose Metabolism Keywords: Type 2 Diabetes, endogenous glucose production, splanchnic glucose uptake, gluconeo-genesis, glycogenolysis, glucose effectiveness.
More informationHorizon Scanning Technology Summary. Liraglutide for type 2 diabetes. National Horizon Scanning Centre. April 2007
Horizon Scanning Technology Summary National Horizon Scanning Centre Liraglutide for type 2 diabetes April 2007 This technology summary is based on information available at the time of research and a limited
More informationAge-adjusted Percentage of U.S. Adults Who Were Obese or Who Had Diagnosed Diabetes
Age-adjusted Percentage of U.S. Adults Who Were Obese or Who Had Diagnosed Diabetes Obesity (BMI 30 kg/m 2 ) 1994 2000 2009 No Data 26.0% Diabetes 1994 2000 2009
More informationGastroparesis: Diagnosis and Management
Gastroparesis: Diagnosis and Management Rodica Pop-Busui MD, PhD Professor of Internal Medicine, Metabolism, Endocrinology and Diabetes, University of Michigan, Ann Arbor, MI Disclosures Astra Zeneca Research
More informationType 2 DM in Adolescents: Use of GLP-1 RA. Objectives. Scope of Problem: Obesity. Background. Pathophysiology of T2DM
Type 2 DM in Adolescents: Use of GLP-1 RA Objectives Identify patients in the pediatric population with T2DM that would potentially benefit from the use of GLP-1 RA Discuss changes in glycemic outcomes
More informationDrug Class Monograph
Drug Class Monograph Class: Dipeptidyl-Peptidase 4 (DPP-4) Inhibitors Drugs: alogliptin, alogliptin/metformin, Januvia (sitagliptin), Janumet (sitagliptin/metformin), Janumet XR (sitagliptin/metformin),
More informationThe landmark Diabetes Control and Complications
The Role of Amylin and Glucagon in the Dampening of Glycemic Excursions in Children With Type 1 Diabetes Rubina A. Heptulla, Luisa M. Rodriguez, Lisa Bomgaars, and Morey W. Haymond Postprandial hyperglycemia
More informationIncredible Incretins Abby Frye, PharmD, BCACP
Incredible Incretins Abby Frye, PharmD, BCACP Objectives & Disclosures Review the pathophysiology of T2DM and the impact of the incretin system Describe the defining characteristics of the available glucagonlike
More informationDiabetes Update: Intensifying Insulin Therapy Nuts, Bolts and Other Items
Diabetes Update: Intensifying Insulin Therapy Nuts, Bolts and Other Items Hayley A. Miller, MD Physician, Internal Medicine, Diabetes and Metabolism, Sandy Clinic, Intermountain Healthcare Objectives:
More informationNewer Insulins. Boca Raton Regional Hospital 15th Annual Internal Medicine Conference
Newer Insulins Boca Raton Regional Hospital 15th Annual Internal Medicine Conference Luigi F. Meneghini, MD, MBA Professor of Internal Medicine, UT Southwestern Medical Center Executive Director, Global
More informationSIMPLICITY IN T2DM MANAGEMENT WITH DPP4 INHIBITORS: SPECIAL POPULATION
SIMPLICITY IN T2DM MANAGEMENT WITH DPP4 INHIBITORS: SPECIAL POPULATION DR ROSE ZHAO-WEI TING ( 丁昭慧醫生 ) MBBS (HK), MRCP (UK), FHKCP, FHKAM (MEDICINE) Specialist in Endocrinology, Diabetes and Metabolism
More informationHypoglycemia a barrier to normoglycemia Are long acting analogues and pumps the answer to the barrier??
Hypoglycemia a barrier to normoglycemia Are long acting analogues and pumps the answer to the barrier?? Moshe Phillip Institute of Endocrinology and Diabetes National Center of Childhood Diabetes Schneider
More informationNATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE. Single Technology Appraisal. Canagliflozin in combination therapy for treating type 2 diabetes
NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE Single Technology Appraisal Canagliflozin in combination therapy for Final scope Remit/appraisal objective To appraise the clinical and cost effectiveness
More informationClinical Overview of Combination Therapy with Sitagliptin and Metformin
Clinical Overview of Combination Therapy with Sitagliptin and Metformin 1 Contents Pathophysiology of type 2 diabetes and mechanism of action of sitagliptin Clinical data overview of sitagliptin: Monotherapy
More informationGlyceamic control is indicated by 1. Fasting blood sugar less than 126 mg/dl 2. Random blood sugar 3. HbA1c less than 6.5 % Good glycaemic control
Glyceamic control is indicated by 1. Fasting blood sugar less than 126 mg/dl 2. Random blood sugar 3. HbA1c less than 6.5 % Good glycaemic control can prevent many of early type 1 DM(in DCCT trail ). UK
More informationMae Sheikh-Ali, M.D. Assistant Professor of Medicine Division of Endocrinology University of Florida College of Medicine- Jacksonville
Mae Sheikh-Ali, M.D. Assistant Professor of Medicine Division of Endocrinology University of Florida College of Medicine- Jacksonville Pathogenesis of Diabetes Mellitus (DM) Criteria for the diagnosis
More informationDrug Use Criteria: Glucagon-Like Peptide 1 Receptor Agonists
Texas Vendor Drug Program Drug Use Criteria: Glucagon-Like Peptide 1 Receptor Agonists Publication History Developed February 2006. Revised September 2018; September 2016; June 2015; October 2013; December
More informationDept of Diabetes Main Desk
Dept of Diabetes Main Desk 01202 448060 Glucose management in Type 2 Diabetes in Adults The natural history of type 2 diabetes is for HbA1c to deteriorate with time. A stepwise approach to treatment is
More informationFaculty. Concentrated Insulin: Examining the Necessity of Newer Insulins for In-Hospital Diabetes Management. Disclosures. Learning Objectives
Examining the Necessity of Newer Insulins for In-Hospital Diabetes Management Faculty Susan Cornell, PharmD, CDE, FAPhA, FAADE Associate Professor of Pharmacy Practice Associate Director of Experiential
More information5/12/2011. Recognize the major types of diabetes: Type 2, Type 1A, Type 1B, MODY, LADA, Pancreatic diabetes, drug-induced DM
J. Christopher Lynch, Pharm.D. Professor Acting Associate Dean of Student Affairs Southern Illinois University Edwardsville School of Pharmacy The speaker has no conflicts of interest to disclose Recognize
More informationDiabetes Mellitus. Intended Learning Objectives:
Intended Learning Objectives: Diabetes Mellitus 1. Compare and contrast the differences between the drug therapy recommendations of several of the latest and leading diabetes guidelines. 2. Assess the
More informationDiabesity. Metabolic dysfunction that ranges from mild blood glucose imbalance to full fledged Type 2 DM Signs
Diabesity Metabolic dysfunction that ranges from mild blood glucose imbalance to full fledged Type 2 DM Signs Abdominal obesity Low HDL, high LDL, and high triglycerides HTN High blood glucose (F>100l,
More information